AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body.
To join the study, participants must meet the following conditions:
Participants in this study will be assigned to two different parts of the study depending on their type of tumor: participants with squamous NSCLC will be assigned to Part 1, while participants with non-squamous NSCLC will be assigned to Part 2.
Each participant will be randomly assigned (like a flip of the coin) to one of two treatment groups in a blinded fashion:
Participants will receive their assigned treatment through intravenous (IV) infusions, which means the medicine is given directly into a vein. The treatment will be given in cycles, participants will receive PF-08634404 or Pembrolizumab in combination with chemotherapy followed by maintenance with either PF-08634404 or Pembrolizumab monotherapy (Part 1) or PF-08634404 or Pembrolizumab in combination with a chemotherapeutic drug (Part 2). Participants will continue receiving treatment if it is helping and not experiencing serious side effects.
The study will include regular visits for:
Inclusion Criteria:
Exclusion Criteria:
Participants with known actionable genomic alteration (AGAs), including estimated glomerular filtration rate (EGFR), anaplastic lymphoma kinase (ALK), Repressor of Silencing 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), rearranged during transfection (RET), and mesenchymal-epithelial transition (MET), for which there are available first-line therapies per local standard-of-care (SOC) are ineligible. Documented negative results for EGFR, ALK, and ROS1 AGAs are required for participants with non-squamous histology.
Known active CNS lesions are excluded. Participants with definitively treated brain metastases (surgery and/or radiotherapy) may be eligible. Clinically inactive brain metastases of longest diameter < 1 cm are permitted.
Participants with clinically significant risk of hemorrhage or fistula are excluded.
Participants with any history of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy.
Unresolved toxicities from prior anti-tumor therapy, that did not recover to NCI CTCAE v5.0 Grade 0 or 1.
Known to have a history of a severe allergy to any component of the study intervention, or a history of severe allergic reaction to chimeric or humanized antibody.
History of allogeneic organ / hematopoietic stem cell transplantation.
Participants with any of the following respiratory conditions:
Evidence of noninfectious or drug-induced interstitial lung disease (ILD) or pneumonitis
Grade ≥3 pulmonary disease unrelated to underlying malignancy
History of uncontrolled comorbidities within 6 months prior to the first dose including uncontrolled cardiac and cerebrovascular conditions, hypertension, diabetes, significant vascular disease or arterial/severe venous thromboembolic events.
Major surgery < 4 weeks or minor surgery < 3 days prior to first dose of study intervention.
History of severe bleeding tendency or coagulation dysfunction
History of esophageal varices, severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding within 6 months prior to the first dose.
Participants with acute, chronic or symptomatic infections including participants positive for active HIV, hepatitis B virus (HBV), or Hepatitis C virus (HCV).
Participants with history of immunodeficiency
Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior (in the past 5 years) or laboratory abnormality that may increase the risk of study participation or make the participant inappropriate for the study.
Previous systemic anti-tumor therapy including:
Prior immune-related AE that led to anti-PD-(L)1 treatment discontinuation, adverse events from prior immunotherapy not improved to Grade 1 before screening, or required treatment with systemic immunosuppressive therapy.
Prior and concomitant therapy:
Breastfeeding participants, participants of childbearing potential, and male participants who are unwilling to follow contraceptive measures.
ClinicalTrials.gov_Inquiries@pfizer.com1-800-718-1021
Fountain Valley, California 92708, United States
Glendale, California 91204, United States
N. Venice, Florida 34275, United States
Port Saint Lucie, Florida 34952, United States
Chicago, Illinois 60612, United States
Chicago, Illinois 60612, United States
Peru, Illinois 61354, United States
Coon Rapids, Minnesota 55433, United States
Minneapolis, Minnesota 55407, United States
Saint Paul, Minnesota 55102, United States
Chattanooga, Tennessee 37403, United States
Chattanooga, Tennessee 37404, United States
Knoxville, Tennessee 37909, United States
Nashville, Tennessee 37203, United States
Ciudad Autónoma de Buenos Aires, Buenos Aires C1122AAL, Argentina
Buenos Aires, Buenos Aires F.D. C1425, Argentina
CABA, Buenos Aires F.D. C1430EGF, Argentina
Salvador, Estado de Bahia 41950-640, Brazil
Porto Alegre, Rio Grande do Sul 90050-170, Brazil
Ribeirão Preto, São Paulo 14051-140, Brazil
Toronto, Ontario M5G 2M9, Canada
Chicoutimi, Quebec G7H 5H6, Canada
Greenfield Park, Quebec J4V2H1, Canada
Montreal, Quebec H4J 1C5, Canada
Sherbrooke, Quebec J1H 5N4, Canada
Luoyang, Henan 471000, China
Luoyang, Henan 471003, China
Wuhan, Hubei 430048, China
Nanjing, Jiangsu 210031, China
Hangzhou, Zhejiang 310003, China
Hangzhou, Zhejiang 310016, China
Wenzhou, Zhejiang 325000, China
Limoges, Haute Vienne 87042, France
Hyderabad, Telangana 500034, India
Petach Tikva, Tel Aviv 4941492, Israel
Meldola, FC 47014, Italy
Otashi, Gunma 373-8550, Japan
Higashiibaraki-gun, Ibaraki 311-3193, Japan
Kanazawa, Ishikawa-ken 920-8650, Japan
Hirakata-shi, Osaka 573-1191, Japan
Bunkyo-ku, Tokyo 113-8603, Japan
Bunkyo-ku, Tokyo 113-8677, Japan
Chuo-ku, Tokyo 104-0045, Japan
Shinjyuku-ku, Tokyo 162-8655, Japan
Katowice, 40-514, Poland
Kielce, 25-734, Poland
Opole, 45-061, Poland
Mayagüez, 00680, Puerto Rico
Santiago de Compostela, A Coruña [LA Coruña] 15706, Spain
Valencia, Valenciana, Comunitat 46009, Spain
Changhua County, Changhua 50006, Taiwan
Istanbul, İstanbul 34093, Turkey (Türkiye)
Istanbul, İstanbul 34722, Turkey (Türkiye)
Üsküdar / İstanbul, İ̇stanbul 34662, Turkey (Türkiye)
Ankara, 06200, Turkey (Türkiye)
Ankara, 06560, Turkey (Türkiye)
Gaziantep, 27310, Turkey (Türkiye)